MedDataX Logo

CS Scar Impact on ART Outcomes

NCT ID: NCT06021886

Last Updated: 2023-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

510 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-06-15

Study Completion Date

2024-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CS scar impact on ART outcomes, Retrospective Cohort Study IVF outcome can be affected by the presence of caesarean section scar with or without defect in different ways

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CS scar impact on ART outcomes, Retrospective Cohort Study IVF outcome can be affected by the presence of caesarean section scar with or without defect in different ways; increase difficulty of embryo transfer, presence intrauterine fluid at the time of transfer can affect the chances of embryo implantation and increase the rate of spontaneous miscarriages To compare the success rates and outcomes of pregnancies of frozen embryo transfer for euploid embryos in patients without caesarean section, and who had caesarean section (with or without a NICHE) after euploid embryo transfer. Does CS scar and CS scar defect affect IVF outcome? All women who underwent an embryo transfer with a Euploid embryo between 2015 and 2022, who meet the inclusion criteria will be included in the study.

* Inclusion Criteria: Age 25-40 years old. Euploid embryo transfer. Medically free BMI less tha 30 kg/m2 Hormone therapy preparation for FET.
* Exclusion criteria Previous uterine scar other than cesarean section. Congenital uterine abnormalities Presence of intrauterine lesions e.g., polyp, fibroid, Endometriosis or adenomyosis Hydrosalpinx, Chronic endometritis
* Primary outcome: Clinical pregnancy rate, defined as a pregnancy with a detectable heart rate at 7 weeks of gestation or beyond.
* Secondary outcomes : Early pregnancy complications Ectopic pregnancy or Miscarriage. Caesarean section scar dehiscence or

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fertility Issues

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patient without scar

history of euploid embryo transfer

No interventions assigned to this group

patient with cs scar no Niche

history of euploid embryo transfer

No interventions assigned to this group

patient with cs scar with niche

history of euploid embryo transfer

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 25-40 years old.

Euploid embryo transfer.

Medically free

BMI less tha 30 kg/m2

Hormone therapy preparation for FET.

Exclusion Criteria

Previous uterine scar other than cesarean section.

Congenital uterine abnormalities

Presence of intrauterine lesions e.g., polyp, fibroid,

Endometriosis or adenomyosis

Hydrosalpinx, Chronic endometritis
Minimum Eligible Age

25 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

HealthPlus Fertility Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed Elsayed Hassan Hamed Elbohoty

Reproductive medicine consultant

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

HealthPlus fertility Centre

Abu Dhabi, , United Arab Emirates

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Arab Emirates

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

HealthPLus Dr Ahmed Al Bohoty, consultant

Role: primary

[email protected]
050406730

Waleed Sayed, consultant

Role: backup

[email protected]
0506638001

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

REC/2023/P38

Identifier Type: -

Identifier Source: org_study_id